Drug resistance to schistosomicides and other anthelmintics of medical significance.
It is usual for people to be infected for some period in life with parasitic worms, which may cause morbidity or even kill. Anthelmintics are used for the treatment and control of the human helminthiases, since no vaccines are yet available. Despite the widespread use of these compounds, drug resistance has become apparent only with antischistosomal chemotherapy, in contrast to the situation with other anti-infective agents in human medicine and with veterinary anthelmintics, where resistance is widespread. This paper reviews research on drug resistance in human helminthiasis with emphasis on schistosomicidal drugs.
Brindley
P J
PJ
Tropical Health Program, Queensland Institute of Medical Research, Bancroft Centre, Brisbane, Australia.
D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology* / Q000627:therapeutic use; D001483:Base Sequence; D017931:DNA Primers / Q000737:chemistry; D004351:Drug Resistance / Q000235:genetics; D015321:Gene Rearrangement; D006373:Helminthiasis / Q000188:drug therapy*; D006376:Helminths / Q000187:drug effects; D006801:Humans; D006826:Hycanthone / Q000494:pharmacology / Q000627:therapeutic use; D008969:Molecular Sequence Data; D012547:Schistosoma / Q000187:drug effects*; D012550:Schistosoma mansoni / Q000187:drug effects / Q000235:genetics; D012552:Schistosomiasis / Q000188:drug therapy*; D012556:Schistosomicides / Q000494:pharmacology* / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000871:Anthelmintics; D017931:DNA Primers; D012556:Schistosomicides; D006826:Hycanthone